Michal Sternschuss, Tal Goshen-Lago, Gali Perl, Miki Goldenfeld, Elana Brook, Baroch Brenner, Hanoch Kashtan, Irit Ben Aharon, Riad Haddad
Davidoff Cancer Center, Rabin Medical Center, Division of Oncology, Petah Tikva 69978, Israel.
Division of Oncology, Rambam Health Care Campus, Haifa 3109601, Israel.
J Pers Med. 2021 Oct 21;11(11):1059. doi: 10.3390/jpm11111059.
Unfortunately, the majority of patients with colorectal cancer liver metastases (CRCLM) experience disease recurrence following hepatic surgery. The key challenge is therefore optimal patient selection, which currently relies on anatomical and clinical parameters. Exploring a potential molecular signature may be predictive for seeing a clinical benefit from CRCLM resection.
Consecutive patients who underwent CRCLM resection at our medical center between 2006 and 2016 were divided into cohorts of "good prognosis" (GP) or "poor prognosis" (PP) based on the time interval between their resection and disease recurrence. Proteomic analysis was performed on the surgical specimen and correlation analysis was carried out with demographics and clinical outcomes.
Proteomic analysis revealed 99 differentially expressed proteins of which a third were associated with extracellular matrix (ECM) pathways as the matrix metalloproteinases (MMPs). Multivariate analysis yielded a statistically differential proteomic pattern between the cohort regardless of perioperative treatment.
Our results indicate a different proteomic landscape in the cohort of patients who had a clinical benefit from CRCLM resection which appears to be correlated with ECM pathways. Further prospective studies are needed to define the role of ECM pathways in prognostics and patient selection for surgical procedures for CRCLM.
不幸的是,大多数结直肠癌肝转移(CRCLM)患者在肝脏手术后会出现疾病复发。因此,关键挑战在于优化患者选择,目前这依赖于解剖学和临床参数。探索潜在的分子特征可能有助于预测CRCLM切除术后是否能获得临床益处。
将2006年至2016年期间在我们医疗中心接受CRCLM切除的连续患者,根据其切除与疾病复发之间的时间间隔,分为“预后良好”(GP)或“预后不良”(PP)队列。对手术标本进行蛋白质组分析,并与人口统计学和临床结果进行相关性分析。
蛋白质组分析揭示了99种差异表达蛋白,其中三分之一与细胞外基质(ECM)途径相关,如基质金属蛋白酶(MMPs)。多变量分析显示,无论围手术期治疗如何,队列之间存在统计学上的差异蛋白质组模式。
我们的结果表明,从CRCLM切除术中获得临床益处的患者队列具有不同的蛋白质组格局,这似乎与ECM途径相关。需要进一步的前瞻性研究来确定ECM途径在CRCLM手术预后和患者选择中的作用。